FDA Status
FDA-Approved (3 indications)
Mounjaro (T2D, 2022) · Zepbound (obesity, 2023) · Zepbound OSA expansion (2024)
Claimed Benefits
- Weight loss (20.9% avg at 15 mg over 72 weeks)
- Type 2 diabetes glycemic control (superior to semaglutide)
- Obstructive sleep apnea (AHI reduced up to 62.8%)
- Cardiometabolic markers (lipids, BP, insulin sensitivity)
Clinical Evidence
4+
Pivotal Phase 3 Trials
Phase III
FDA-Approved ×3
SURMOUNT-1 (N=2,539) showed a 20.9% average weight reduction at 15 mg over 72 weeks — more than half of participants on the highest dose lost ≥20% of body weight, a threshold previously only consistently achieved by bariatric surgery.
Read Full Deep Dive
Mechanism, dosing, vendor pricing, and full research citations